Nautilus Biotechnolgy, Inc.(NAUT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NAUT Nautilus Biotechnolgy, Inc.

Market Closed 12-12 16:00:00 EST

1.85

-0.13

-6.57%

盘后1.93

+0.08+4.41%

18:50 EST

High2.03	Low1.85	Vol247.63K
Open2.03	D1 Closing1.98	Amplitude9.34%
Mkt Cap233.66M	Tradable Cap85.62M	Total Shares126.31M
T/O477.08K	T/O Rate0.54%	Tradable Shares46.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NAUT","market":"US","secType":"STK","nameCN":"Nautilus Biotechnolgy, Inc.","latestPrice":1.85,"timestamp":1765573200000,"preClose":1.98,"halted":0,"volume":247630,"hourTrading":{"tag":"盘后","latestPrice":1.9316,"preClose":1.85,"latestTime":"18:50 EST","volume":506,"amount":976.9,"timestamp":1765583449811},"delay":0,"floatShares":46279068,"shares":126305122,"eps":-0.498074,"marketStatus":"Market Closed","change":-0.13,"latestTime":"12-12 16:00:00 EST","open":2.03,"high":2.03,"low":1.845,"amount":477076.454811,"amplitude":0.093434,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.498074,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1596772800000,"exchange":"NASDAQ","adjPreClose":1.98,"preHourTrading":{"tag":"盘前","latestPrice":1.97,"preClose":1.98,"latestTime":"08:50 EST","volume":504,"amount":992.88,"timestamp":1765547446221},"postHourTrading":{"tag":"盘后","latestPrice":1.9316,"preClose":1.85,"latestTime":"18:50 EST","volume":506,"amount":976.9,"timestamp":1765583449811},"volumeRatio":0.9650955228135278,"impliedVol":2.0534,"impliedVolPercentile":0.892},"requestUrl":"/m/hq/s/NAUT/tweets","defaultTab":"tweets","newsList":[{"id":"2588341770","title":"Penny Stocks To Consider In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588341770","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588341770?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:05","pubTimestamp":1764608718,"startTime":"0","endTime":"0","summary":"As December 2025 begins, U.S. stock indexes have slipped, with major tech and cryptocurrency-tied shares experiencing declines amid a broader risk-off sentiment in the market. Despite this cautious atmosphere, investors continue to explore opportunities beyond the well-known large-cap stocks. Penny stocks, though often considered a relic of past market eras, remain relevant for those seeking affordable entry points into companies with growth potential and strong financials.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9612016-choice2-main-header/1585186746976","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9612016-choice2-main-header/1585186746976"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate-management-and-development/nyse-doug/douglas-elliman/news/penny-stocks-to-consider-in-december-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate-management-and-development/nyse-doug/douglas-elliman/news/penny-stocks-to-consider-in-december-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LCUT","FINV","BK4509","LX","BK4209","BK4531","BK4173","BK4526","PRLD","BABB","MAPS","BK4551","BK4139","BK4505","BK4023","BK4579","DOUG","BK4079","TUYA","BK4121","BK4134","BK4113","NAUT","LU0049112450.USD","WDH","DDL","LU1046422090.SGD","LU1235295612.USD","BK4180","CINT","BK4539","BK4166"],"gpt_icon":0},{"id":"2582333812","title":"Nautilus Biotechnology Chief Marketing Officer Kentaro Suzuki Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2582333812","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582333812?lang=en_us&edition=fundamental","pubTime":"2025-11-11 10:29","pubTimestamp":1762828194,"startTime":"0","endTime":"0","summary":"Kentaro Suzuki, Chief Marketing Officer of Nautilus Biotechnology Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDLblRY56:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nautilus Biotechnology Chief Marketing Officer Kentaro Suzuki Acquires Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAUT"],"gpt_icon":0},{"id":"2580782798","title":"Nautilus Biotechnology Regains Nasdaq Compliance After Transfer to Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2580782798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580782798?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:01","pubTimestamp":1762254076,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology Inc. has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. After previously transferring from the Nasdaq Global Select Market due to its stock trading below $1.00 for an extended period earlier this year, the company received notice on November 3, 2025, that its closing bid price met or exceeded $1.00 for at least ten consecutive business days. As a result, the matter is now closed, and Nautilus remains listed on The Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system opera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL5kbldC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAUT","BK4121"],"gpt_icon":0},{"id":"2580134213","title":"Nautilus Biotechnology Unveils Reproducible Single-Molecule Proteomics Data at Buck Institute","url":"https://stock-news.laohu8.com/highlight/detail?id=2580134213","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580134213?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:02","pubTimestamp":1762174954,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology Inc. has announced the successful installation and testing of its first external field evaluation unit at the Buck Institute for Research on Aging. Over six months, researchers at the Buck Institute used Nautilus' next-generation single-molecule proteomics platform to generate highly reproducible data from neurodegenerative disease samples, including novel insights into tau proteoforms. These results validate the platform's robust performance and its potential to advance understanding of aging and neurodegeneration, such as Alzheimer's disease. The scientific findings from this collaboration will be presented at the 2025 HUPO World Congress seminar, \"Redefining Proteomics with Single-Molecule Iterative Mapping,\" scheduled for November 10, 2025, in Toronto.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL7GwGyQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","BK4585","BK4121","NAUT","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2579516778","title":"Nautilus Biotechnology Faces Nasdaq Delisting Risk Amid Compliance Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2579516778","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579516778?lang=en_us&edition=fundamental","pubTime":"2025-10-30 14:01","pubTimestamp":1761804068,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnolgy, Inc. (NAUT) has disclosed a new risk, in the Share Price & Shareholder Rights category. Nautilus Biotechnology, Inc. faces a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nautilus-biotechnology-faces-nasdaq-delisting-risk-amid-compliance-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nautilus-biotechnology-faces-nasdaq-delisting-risk-amid-compliance-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","TQQQ","MNQmain","TSYW.SI","USJW.SI","QLD","PSQ","NVIW.SI","QID","NQmain","USAW.SI","NAUT","SQQQ",".IXIC"],"gpt_icon":0},{"id":"1188043808","title":"Nautilus Q3 2025 Earnings Call Summary and Q&A Highlights: Tau Assay Progress and Strategic Collaborations","url":"https://stock-news.laohu8.com/highlight/detail?id=1188043808","media":"Earnings Call","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188043808?lang=en_us&edition=fundamental","pubTime":"2025-10-29 06:11","pubTimestamp":1761689481,"startTime":"0","endTime":"0","summary":"[Management View]Nautilus Biotechnology reported significant progress in external validation of its proteomics platform, highlighted by new Tau assay data set for external presentation at a leading...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAUT"],"gpt_icon":0},{"id":"2579191314","title":"Nautilus (NAUT) Q3 2025 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2579191314","media":"Motley Fool Transcribing","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579191314?lang=en_us&edition=fundamental","pubTime":"2025-10-29 05:55","pubTimestamp":1761688537,"startTime":"0","endTime":"0","summary":"DateTuesday, Oct. 28, 2025, at 8:30 a.m. ETCall participantsChief Executive Officer — Sujal PatelChief Marketing Officer — Kentaro SuzukiChief Financial Officer — Anna MowryNeed a quote from a Motley Fool analyst?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_motley_transcript","url":"https://www.fool.com/earnings/call-transcripts/2025/10/28/nautilus-naut-q3-2025-earnings-call-transcript/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/10/28/nautilus-naut-q3-2025-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["NAUT"],"gpt_icon":0},{"id":"2579974839","title":"Nautilus Biotechnolgy (NAUT) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2579974839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579974839?lang=en_us&edition=fundamental","pubTime":"2025-10-29 04:45","pubTimestamp":1761684331,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Daniel Brennan reiterated a Buy rating on Nautilus Biotechnolgy today. The company’s shares closed today at $1.43. Brennan covers ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nautilus-biotechnolgy-naut-gets-a-buy-from-td-cowen-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nautilus-biotechnolgy-naut-gets-a-buy-from-td-cowen-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","NAUT","TD","COWN","BK4566","BK4585","BK4121","BK4207"],"gpt_icon":0},{"id":"2578956053","title":"BRIEF-Nautilus Biotechnology Q3 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2578956053","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578956053?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652851,"startTime":"0","endTime":"0","summary":"BRIEF-Nautilus Biotechnology Q3 EPS USD -0.11\n\n\nOct 28 (Reuters) - Nautilus Biotechnology Q3 operating expenses USD 15.472 million.\n\nQ3 net income USD -13.574 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nPLXC2C96C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAUT"],"gpt_icon":0},{"id":"2578959687","title":"Nautilus Biotechnology Inc - Early Access Program With Tau Proteoforms Expected in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2578959687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578959687?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nPLXC2C96C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAUT"],"gpt_icon":0},{"id":"2578956408","title":"Nautilus Biotechnology Q3 Net Income USD -13.574 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2578956408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578956408?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652806,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nPLXC2C96C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAUT"],"gpt_icon":0},{"id":"2578395626","title":"Nautilus Biotechnology Q3 Operating Expenses USD 15.472 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2578395626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578395626?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652806,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nPLXC2C96C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAUT","BK4121"],"gpt_icon":0},{"id":"2578959363","title":"Press Release: Nautilus Biotechnology Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2578959363","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578959363?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652800,"startTime":"0","endTime":"0","summary":"SEATTLE, Oct. 28, 2025  -- Nautilus Biotechnology, Inc. , a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025.-- Continued progress was made in processing Tau proteoform samples from. collaborators in support of our goals of product validation and growing. our publications. We expect to share this data at the upcoming World HUPO. format, which is intended to support our forthcoming commercial launch in. Net loss was $13.6 million for the third quarter of 2025, as compared to the net loss of $16.4 million for the corresponding prior year period.With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratiz","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAUT","BK4121"],"gpt_icon":0},{"id":"2578329909","title":"BRIEF-Nautilus Biotechnology Inc - Quarterly Net Loss Per Share $0.11 - Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2578329909","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578329909?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:22","pubTimestamp":1761646954,"startTime":"0","endTime":"0","summary":"BRIEF-Nautilus Biotechnology Inc - Quarterly Net Loss Per Share $0.11 - FilingOct 28  - Nautilus Biotechnology Inc NAUT.O:NAUTILUS BIOTECHNOLOGY INC - QTRLY NET LOSS PER SHARE $0.11 - FILINGNAUTILUS BIOTECHNOLOGY INC -  EXPECT TO LAUNCH EARLY ACCESS PROGRAM WITH TAU PROTEOFORMS IN THE FIRST HALF OF 2026Source text: [ID:n0001808805-25-000077]Further company coverage: NAUT.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90UL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAUT","BK4121"],"gpt_icon":0},{"id":"2578993470","title":"Nautilus Biotechnology Q3 EPS $(0.11) Beats $(0.15) Estimate. Cash And Equivalents Of $168.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2578993470","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578993470?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:16","pubTimestamp":1761646577,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 15.38 percent increase over losses of $(0.13) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/10/48455981/nautilus-biotechnology-q3-eps-0-11-beats-0-15-estimate-cash-and-equivalents-of-168-5m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","USAW.SI",".IXIC","SQQQ","NQmain","NVIW.SI","USJW.SI","MNQmain","NAUT","PSQ","TQQQ","QID","TSYW.SI","BK4121"],"gpt_icon":0},{"id":"2578934185","title":"Nautilus Biotechnology Inc -  Expect to Launch Early Access Program With Tau Proteoforms in the First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2578934185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578934185?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:10","pubTimestamp":1761646205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90UL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAUT","BK4121"],"gpt_icon":0},{"id":"2578180934","title":"Nautilus Biotechnology Inc - Qtrly Net Loss per Share $0.11 - Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2578180934","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578180934?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:10","pubTimestamp":1761646205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90UL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAUT"],"gpt_icon":0},{"id":"2578934337","title":"Nautilus Biotechnology posts Q3 net loss of $13.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2578934337","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578934337?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:03","pubTimestamp":1761645796,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology Inc. reported financial results for the third quarter ended September 30, 2025. Operating expenses were $15.5 million for the third quarter, down 19% from $19.1 million in the same period last year. Net loss for the quarter was $13.6 million, compared to a net loss of $16.4 million for the prior year period. Cash, cash equivalents, and investments totaled $168.5 million as of September 30, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 28, 2025, and is solely responsible for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDLbG985j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAUT"],"gpt_icon":0},{"id":"2577551197","title":"Nautilus Biotechnology Inc  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2577551197","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577551197?lang=en_us&edition=fundamental","pubTime":"2025-10-24 21:15","pubTimestamp":1761311706,"startTime":"0","endTime":"0","summary":"Nautilus Biotechnology Inc  expected to post a loss of15cents a share - Earnings Preview Nautilus Biotechnology Inc NAUT.OQ NAUT.O is expected to  show no change in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nL8N3W51EW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAUT"],"gpt_icon":0},{"id":"2573995758","title":"Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573995758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573995758?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:00","pubTimestamp":1759838400,"startTime":"0","endTime":"0","summary":"SEATTLE, Oct.  07, 2025  (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will repor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/07/3162416/0/en/Nautilus-Biotechnology-to-Announce-Third-Quarter-2025-Financial-Results-on-October-28-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAUT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nautilus.bio","stockEarnings":[{"period":"1week","weight":-0.0887},{"period":"1month","weight":0.0694},{"period":"3month","weight":1.5669},{"period":"6month","weight":1.6391},{"period":"1year","weight":-0.0931},{"period":"ytd","weight":0.1012}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.033973},{"month":2,"riseRate":0.6,"avgChangeRate":0.045091},{"month":3,"riseRate":0.6,"avgChangeRate":0.004911},{"month":4,"riseRate":0.2,"avgChangeRate":-0.103794},{"month":5,"riseRate":0.6,"avgChangeRate":-0.003176},{"month":6,"riseRate":0.2,"avgChangeRate":-0.022509},{"month":7,"riseRate":0.6,"avgChangeRate":-0.017062},{"month":8,"riseRate":0.2,"avgChangeRate":-0.079652},{"month":9,"riseRate":0.5,"avgChangeRate":0.010868},{"month":10,"riseRate":0.333333,"avgChangeRate":0.046365},{"month":11,"riseRate":0.5,"avgChangeRate":0.048822},{"month":12,"riseRate":0.5,"avgChangeRate":-0.040612}],"exchange":"NASDAQ","name":"Nautilus Biotechnolgy, Inc.","nameEN":"Nautilus Biotechnolgy, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nautilus Biotechnolgy, Inc.(NAUT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nautilus Biotechnolgy, Inc.(NAUT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nautilus Biotechnolgy, Inc.,NAUT,Nautilus Biotechnolgy, Inc.股票,Nautilus Biotechnolgy, Inc.股票老虎,Nautilus Biotechnolgy, Inc.股票老虎国际,Nautilus Biotechnolgy, Inc.行情,Nautilus Biotechnolgy, Inc.股票行情,Nautilus Biotechnolgy, Inc.股价,Nautilus Biotechnolgy, Inc.股市,Nautilus Biotechnolgy, Inc.股票价格,Nautilus Biotechnolgy, Inc.股票交易,Nautilus Biotechnolgy, Inc.股票购买,Nautilus Biotechnolgy, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nautilus Biotechnolgy, Inc.(NAUT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nautilus Biotechnolgy, Inc.(NAUT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction